Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NLD001
MIFTS: 51

Nail Disease

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Nail Disease

About this section

MalaCards integrated aliases for Nail Disease:

Name: Nail Disease 12 6 15
Nail Diseases 43 44 73
Abnormality of the Nail 29 6

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases Fetal diseases
Anatomical: Skin diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:4123
ICD9CM 35 703 703.9
MeSH 44 D009260
SNOMED-CT 68 17790008
UMLS 73 C0027339
Sources

Summaries for Nail Disease

About this section
MedlinePlus : 43 Your toenails and fingernails protect the tissues of your toes and fingers. They are made up of layers of a hardened protein called keratin, which is also in your hair and skin. The health of your nails can be a clue to your overall health. Healthy nails are usually smooth and consistent in color. Specific types of nail discoloration and changes in growth rate can be signs of lung, heart, kidney, and liver diseases, as well as diabetes and anemia. White spots and vertical ridges are harmless. Nail problems that sometimes require treatment include Bacterial and fungal infections Ingrown nails Tumors Warts Keeping your nails clean, dry, and trimmed can help you avoid some problems. Do not remove the cuticle, which can cause infection.

MalaCards based summary : Nail Disease, also known as nail diseases, is related to paronychia and tooth agenesis, selective, 4, and has symptoms including pruritus, exanthema and clubbing of nail. An important gene associated with Nail Disease is FZD6 (Frizzled Class Receptor 6), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Chlorhexidine and Phenol have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and kidney, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 An integumentary system disease that is located in nail.

Wikipedia : 76 A nail disease or onychosis is a disease or deformity of the nail. Although the nail is a structure... more...

Sources

Related Diseases for Nail Disease

About this section

Diseases in the Nail Disease family:

Nail Disorder, Nonsyndromic Congenital, 6 Nail Disorder, Nonsyndromic Congenital, 2
Nail Disorder, Nonsyndromic Congenital, 3 Nail Disorder, Nonsyndromic Congenital, 1
Nail Disorder, Nonsyndromic Congenital, 5 Nail Disorder, Nonsyndromic Congenital, 4
Nail Disorder, Nonsyndromic Congenital, 7 Nail Disorder, Nonsyndromic Congenital, 8
Nail Disorder, Nonsyndromic Congenital, 9 Nail Disorder, Nonsyndromic Congenital, 10

Diseases related to Nail Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 38)
# Related Disease Score Top Affiliating Genes
1 paronychia 10.9
2 tooth agenesis, selective, 4 10.8
3 nail-patella syndrome 10.8
4 keratosis palmoplantaris striata ii 10.8
5 nail disorder, nonsyndromic congenital, 1 10.2 AIRE FZD6
6 psoriatic arthritis 10.2
7 arthritis 10.2
8 acute generalized exanthematous pustulosis 10.1 IL17A IL17F
9 immunodeficiency 17 10.1 CARD9 STAT1
10 psoriasis 10.1
11 autoimmune polyendocrine syndrome type 1 10.1 AIRE IL17A
12 axillary adenitis 10.1 IL12RB1 STAT1
13 nasopharyngitis 10.1 IL17A IL17RA
14 phaeohyphomycosis 10.1 CARD9 STAT1
15 stromal keratitis 10.1 IL17A IL17RA
16 candidiasis, familial, 2 10.1 CARD9 CLEC7A
17 familial candidiasis 10.1 CARD9 IL17F IL17RA
18 nail disorder, nonsyndromic congenital, 10 10.0
19 subcutaneous mycosis 10.0 CARD9 CLEC7A
20 chromoblastomycosis 10.0 CARD9 CLEC7A
21 coccidioidomycosis 10.0 CARD9 CLEC7A STAT1
22 primary systemic mycosis 9.9 CARD9 CLEC7A IL17A
23 hidradenitis suppurativa 9.9 IL12RB1 IL17A
24 hidradenitis 9.9 IL12RB1 IL17A
25 nail disorder, nonsyndromic congenital, 4 9.8 CEP76 RSPO4 ZNF519
26 enthesopathy 9.8
27 cleft palate, isolated 9.7
28 pemphigus vulgaris, familial 9.7
29 pemphigus vulgaris 9.7
30 lymphoma 9.7
31 pustulosis of palm and sole 9.7
32 dermatophytosis 9.7
33 pemphigus 9.7
34 cleft lip 9.7
35 viral infectious disease 9.7
36 opportunistic mycosis 9.6 AIRE CARD9 CLEC7A IL17A IL17RA STAT1
37 chronic mucocutaneous candidiasis 9.5 AIRE CARD9 CLEC7A IL17A IL17F IL17RA
38 candidiasis 9.5 AIRE CARD9 CLEC7A IL17A IL17F IL17RA

Graphical network of the top 20 diseases related to Nail Disease:



Diseases related to Nail Disease
Sources

Symptoms & Phenotypes for Nail Disease

About this section

UMLS symptoms related to Nail Disease:


pruritus, exanthema, clubbing of nail

MGI Mouse Phenotypes related to Nail Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 AIRE CARD9 CEP76 CLEC7A EGFR IL12RB1
2 digestive/alimentary MP:0005381 9.73 AIRE CLEC7A EGFR IL17A IL17F STAT1
3 immune system MP:0005387 9.7 AIRE CARD9 CEP76 CLEC7A EGFR IL12RB1
4 respiratory system MP:0005388 9.1 AIRE CLEC7A EGFR IL17A IL17F IL17RA
Sources

Drugs & Therapeutics for Nail Disease

About this section

Drugs for Nail Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
2
Phenol Approved, Experimental Phase 4,Not Applicable 108-95-2 996
3
Ethanol Approved Phase 4 64-17-5 702
4
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
7
Bifonazole Approved, Investigational Phase 4,Phase 3,Not Applicable 60628-96-8 2378
8
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 1549008 5402
9
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
10
Polihexanide Approved, Investigational Phase 4 28757-47-3
11
Etanercept Approved, Investigational Phase 4 185243-69-0
12
Lenograstim Approved, Investigational Phase 4 135968-09-1
13
Docetaxel Approved, Investigational Phase 4,Phase 3,Not Applicable 114977-28-5 148124
14
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
15
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
16
Apremilast Approved, Investigational Phase 4,Phase 2 608141-41-9 11561674
17
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
18
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
19
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21 Anti-Infective Agents, Local Phase 4,Not Applicable
22 Central Nervous System Depressants Phase 4
23 Chlorhexidine gluconate Phase 4
24 Disinfectants Phase 4
25 Dermatologic Agents Phase 4,Phase 2,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Keratolytic Agents Phase 4,Not Applicable
29 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
35 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 2
38 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
39 Analgesics, Non-Narcotic Phase 4,Phase 2
40 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
41 Gastrointestinal Agents Phase 4,Phase 2
42 Analgesics Phase 4,Phase 2
43 Immunologic Factors Phase 4,Phase 2,Phase 1
44 Anti-Inflammatory Agents Phase 4,Phase 2
45 Antirheumatic Agents Phase 4,Phase 2
46 Adjuvants, Immunologic Phase 4
47 Antimitotic Agents Phase 4,Phase 3
48
Hydroxyitraconazole Phase 4,Phase 3,Phase 2
49 Micronutrients Phase 4
50 Folate Phase 4

Interventional clinical trials:

(show top 50) (show all 142)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy Unknown status NCT01844141 Phase 4 70% alcohol;70% alcohol - 0.5% clorhexidine
2 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
3 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
4 Efficacy of Intraoperative Surgical Scrubbing in Reducing Bacterial Load After Nail Removal Surgery Completed NCT01330706 Phase 4 Polihexanide
5 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
6 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
7 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
8 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
9 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
10 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
11 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
12 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
13 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
14 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
15 Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
16 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
17 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
18 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
19 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
20 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
21 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Enrolling by invitation NCT03022617 Phase 4 Apremilast
22 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease Not yet recruiting NCT03263624 Phase 4 Tazarotene Cream 0.1%
23 Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Unknown status NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
24 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
25 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
26 Evaluation of the Cryotherapy in the Prevention of Nails Toxicity Induced by Taxotere® in Breast or Prostate Cancer Completed NCT00925418 Phase 3
27 Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
28 Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails Completed NCT00999687 Phase 2, Phase 3 Indigo Naturalis Extract in Oil
29 Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
30 Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population Completed NCT02547701 Phase 3 P-3058
31 Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
32 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
33 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
34 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
35 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
36 PinPointe FootLaser for the Treatment of Onychomycosis Completed NCT00935649 Phase 2, Phase 3
37 Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
38 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
39 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
40 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
41 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Active, not recruiting NCT03168841 Phase 3 Efinaconazole Topical
42 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
43 Antifungal Drugs in Treatment of Onychomycosis Not yet recruiting NCT03171584 Phase 3 Terbinafine
44 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Not yet recruiting NCT02961634 Phase 3 Ciclopirox 8%
45 Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
46 Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208129 Phase 3 NAB001;Placebo control
47 Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
48 Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis Unknown status NCT01528813 Phase 2 Amorolfine lacquer
49 Using Light Therapy to Treat Toe Nail Fungus Unknown status NCT00771732 Phase 2
50 Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita Unknown status NCT00936533 Phase 2 Dysport® (Botulinumtoxin A (Btx A));Placebo

Search NIH Clinical Center for Nail Disease

Cochrane evidence based reviews: nail diseases

Sources

Genetic Tests for Nail Disease

About this section

Genetic tests related to Nail Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Nail 29
Sources

Anatomical Context for Nail Disease

About this section

MalaCards organs/tissues related to Nail Disease:

41
Skin, Lung, Kidney, Liver, Heart, Bone, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Nail Disease:

19
Nail
Sources

Publications for Nail Disease

About this section

Articles related to Nail Disease:

(show top 50) (show all 77)
# Title Authors Year
1
MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. ( 29531786 )
2018
2
The microvascular and morphostructural changes of nails in psoriatic patients with nail disease; a link between ultrasound and videocapillaroscopy findings in the nailfold. ( 29730685 )
2018
3
The microbial flora of taxane therapy-associated nail disease in cancer patients. ( 29447679 )
2018
4
Rare Variant of Ankyloblepharon-ectodermal Defect-cleft Lip/Cleft Palate Syndrome: Curly Hair-ankyloblepharon-nail Disease Syndrome. ( 29440852 )
2018
5
Reply to: "The microbial flora of taxane therapy-associated nail disease in cancer patients". ( 29447686 )
2018
6
Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. ( 30246363 )
2018
7
Hair and nail diseases in the mature patient. ( 29566920 )
2018
8
Biotin for the treatment of nail disease: what is the evidence? ( 29057689 )
2017
9
Pediatric nail diseases: clinical pearls. ( 28319636 )
2017
10
Nail unit ultrasound: a complete guide of the nail diseases. ( 28900518 )
2017
11
Detection of subclinical ultrasound enthesopathy and nail disease in patients at risk of psoriatic arthritis. ( 27932277 )
2016
12
Intralesional Injection for Inflammatory Nail Diseases. ( 26808185 )
2016
13
Nail Disease for the Primary Care Provider. ( 26476249 )
2015
14
Optimal management of nail disease in patients with psoriasis. ( 29387579 )
2015
15
Ultrasound in the management of nail disease. ( 26895940 )
2015
16
Clinical photography of nail diseases: a simple method to include all fingernails in a frame. ( 25497942 )
2015
17
UV-curable gel formulations: Potential drug carriers for the topical treatment of nail diseases. ( 26187167 )
2015
18
Psoriatic nail disease, a predictor of psoriatic arthritis. ( 25409998 )
2014
19
Potential use of optical coherence tomography and high-frequency ultrasound for the assessment of nail disease in psoriasis and psoriatic arthritis. ( 23988587 )
2013
20
Drug-related nail disease. ( 24079591 )
2013
21
Metoprolol-induced psoriatic nail disease. ( 22724586 )
2013
22
Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. ( 23423871 )
2013
23
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. ( 24117389 )
2013
24
Iontophoresis for treating nail diseases. ( 23738661 )
2013
25
Assessment of psoriatic nail disease activity by rheumatologists: comment on the article by Lubrano et al. ( 22623218 )
2012
26
Patient assessments of skin, joint, and nail disease activity in psoriatic arthritis. ( 22383354 )
2012
27
Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. ( 22156725 )
2012
28
Nail disease in psoriatic arthritis: distal phalangeal bone edema detected by magnetic resonance imaging predicts development of onycholysis and hyperkeratosis. ( 22337245 )
2012
29
Optical coherence tomography: a new tool to assess nail disease in psoriasis? ( 21791896 )
2011
30
Nutrition and nail disease. ( 20620759 )
2010
31
Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. ( 21174373 )
2010
32
Clinical practice. Fungal nail disease. ( 19439745 )
2009
33
Psoriatic nail disease: quality of life and treatment. ( 19799826 )
2009
34
The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? ( 19424069 )
2009
35
Nail disease in pemphigus vulgaris. ( 19903430 )
2009
36
Management of psoriatic nail disease. ( 19341941 )
2009
37
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. ( 18083272 )
2008
38
Two case reports: treating common nail diseases and injuries. ( 17905360 )
2007
39
Therapies for psoriatic nail disease. A systematic review. ( 16724366 )
2006
40
Alefacept treatment of psoriatic nail disease: how severe should nail psoriasis be? ( 16546613 )
2006
41
Alefacept in the treatment of psoriatic nail disease: a proof of concept study. ( 16673801 )
2006
42
Nail diseases related to nail cosmetics. ( 16677969 )
2006
43
Childhood nail diseases. ( 16798433 )
2006
44
Drug-induced nail diseases. ( 16798438 )
2006
45
Alefacept in the treatment of psoriatic nail disease: a small case series. ( 15928640 )
2005
46
Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. ( 18360572 )
2005
47
Molecular genetics of hereditary hair and nail disease. ( 15468149 )
2004
48
Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. ( 15113998 )
2004
49
One interpretation of a psychometric study of patients with nail disease. ( 12664041 )
2003
50
Observer agreement in recording the clinical signs of nail disease and the accuracy of a clinical diagnosis of fungal and non-fungal nail disease. ( 12653750 )
2003
Sources

Variations for Nail Disease

About this section

ClinVar genetic disease variations for Nail Disease:

6 (show all 12)
# Gene Variation Type Significance SNP ID Assembly Location
1 FZD6 NM_003506.3(FZD6): c.1750G> T (p.Glu584Ter) single nucleotide variant Pathogenic rs151339002 GRCh37 Chromosome 8, 104342091: 104342091
2 FZD6 NM_003506.3(FZD6): c.1750G> T (p.Glu584Ter) single nucleotide variant Pathogenic rs151339002 GRCh38 Chromosome 8, 103329863: 103329863
3 FZD6 NM_003506.3(FZD6): c.1531C> T (p.Arg511Cys) single nucleotide variant Pathogenic rs151339003 GRCh37 Chromosome 8, 104340634: 104340634
4 FZD6 NM_003506.3(FZD6): c.1531C> T (p.Arg511Cys) single nucleotide variant Pathogenic rs151339003 GRCh38 Chromosome 8, 103328406: 103328406
5 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh37 Chromosome 1, 151378740: 151378740
6 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh38 Chromosome 1, 151406264: 151406264
7 PKD1 NM_001009944.2(PKD1): c.226C> T (p.His76Tyr) single nucleotide variant Uncertain significance rs932577597 GRCh38 Chromosome 16, 2119368: 2119368
8 PKD1 NM_001009944.2(PKD1): c.226C> T (p.His76Tyr) single nucleotide variant Uncertain significance rs932577597 GRCh37 Chromosome 16, 2169369: 2169369
9 SETBP1 NM_015559.2(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic GRCh38 Chromosome 18, 44951954: 44951954
10 SETBP1 NM_015559.2(SETBP1): c.2614G> A (p.Gly872Arg) single nucleotide variant Likely pathogenic GRCh37 Chromosome 18, 42531919: 42531919
11 OFD1 NM_003611.2(OFD1): c.1999G> A (p.Ala667Thr) single nucleotide variant Uncertain significance GRCh38 Chromosome X, 13760459: 13760459
12 OFD1 NM_003611.2(OFD1): c.1999G> A (p.Ala667Thr) single nucleotide variant Uncertain significance GRCh37 Chromosome X, 13778578: 13778578
Sources

Expression for Nail Disease

About this section
Search GEO for disease gene expression data for Nail Disease.
Sources

Pathways for Nail Disease

About this section

Pathways related to Nail Disease according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Akt Signaling 64
Show member pathways
 13.12 EGFR IL12RB1 IL17A IL17RA PLCD1 STAT1
2
Cytokine Signaling in Immune system 66
Show member pathways
 13.04 EGFR IL12RB1 IL17A IL17F IL17RA STAT1
3
Th17 cell differentiation 37
Show member pathways
 12.24 IL12RB1 IL17A IL17F STAT1
4
Immune response IL-23 signaling pathway 22
Show member pathways
 12.09 EGFR IL12RB1 IL17A IL17F STAT1
5
Tuberculosis 37
11.98 CARD9 CLEC7A STAT1
6
C-type lectin receptor signaling pathway 37
Show member pathways
 11.95 CARD9 CLEC7A STAT1
7
Colorectal Cancer Metastasis 64
11.92 EGFR FZD6 STAT1
8
UVA-Induced MAPK Signaling 64
Show member pathways
 11.75 EGFR PLCD1 STAT1
9
Interleukin-4 and 13 signaling 66
11.6 IL17A IL17F STAT1
10
Jak-Stat Signaling Pathway (sino) 67
11.55 EGFR IL12RB1 STAT1
11
Glioblastoma Multiforme 64
11.54 EGFR FZD6 PLCD1
12
Th1 Differentiation Pathway 65
Show member pathways
 11.37 IL12RB1 IL17A IL17F STAT1
13
Regulation of FZD by ubiquitination 66
Show member pathways
 11.05 FZD6 RSPO4
14
EGF receptor (ErbB1) signaling pathway 1
10.91 EGFR STAT1
15
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 10.89 IL12RB1 IL17A IL17F IL17RA
16
Transcription_Transcription factor Tubby signaling pathways 22
10.85 EGFR PLCD1 STAT1
Sources

GO Terms for Nail Disease

About this section

Biological processes related to Nail Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.71 IL12RB1 IL17A IL17F STAT1
2 defense response to fungus GO:0050832 9.48 IL17A IL17RA
3 positive regulation of defense response to virus by host GO:0002230 9.46 IL12RB1 STAT1
4 positive regulation of interleukin-6 secretion GO:2000778 9.43 IL17A IL17F
5 positive regulation of interleukin-23 production GO:0032747 9.37 IL17A IL17RA
6 fibroblast activation GO:0072537 9.32 IL17A IL17RA
7 regulation of interleukin-6 biosynthetic process GO:0045408 9.26 CARD9 IL17F
8 regulation of interleukin-2 biosynthetic process GO:0045076 9.16 CARD9 IL17F
9 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.13 IL17A IL17F IL17RA
10 interleukin-17-mediated signaling pathway GO:0097400 8.8 IL17A IL17F IL17RA
Sources

Sources for Nail Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....